PROCEPT BioRobotics to Present at the 2023 Wells Fargo Healthcare Conference in Boston
18 8월 2023 - 5:05AM
PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical
robotics company focused on advancing patient care by developing
transformative solutions in urology, today announced that members
of management will present at the upcoming 2023 Wells Fargo
Healthcare Conference in Boston. Management is scheduled to present
on Thursday, September 7 at 3:00 p.m. Eastern Time. A live webcast
of the event, as well as an archived recording, will be available
on the “Investors” section of the company’s website at:
https://ir.procept-biorobotics.com. The webcasts will be archived
and available for replay for at least 90 days after the event.
About PROCEPT BioRobotics
CorporationPROCEPT BioRobotics is a surgical robotics
company focused on advancing patient care by developing
transformative solutions in urology. PROCEPT BioRobotics develops,
manufactures and sells the AquaBeam Robotic System, an advanced,
image-guided, surgical robotic system for use in minimally invasive
urologic surgery with an initial focus on treating benign prostatic
hyperplasia, or BPH. BPH is the most common prostate disease and
impacts approximately 40 million men in the United States. PROCEPT
BioRobotics designed Aquablation therapy to deliver effective, safe
and durable outcomes for males suffering from lower urinary tract
symptoms, or LUTS, due to BPH that are independent of prostate size
and shape or surgeon experience. The Company has developed a
significant and growing body of clinical evidence, which includes
nine clinical studies and over 150 peer-reviewed publications,
supporting the benefits and clinical advantages of Aquablation
therapy.
Investor Contact:Matt Bacso, CFAVP, Investor
Relations and Business
Operationsm.bacso@procept-biorobotics.com
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024